Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension.

Omer Ersin Muz,Mete Guler,Tuncay Pirdal,Kenan Dagdelen

doi:10.1007/s10792-021-01947-2

Omer Ersin Muz, Mete Guler + Show 2 more

Open Access

https://doi.org/10.1007/s10792-021-01947-2

Copy DOI

Abstract

To compare the effect of two different prostaglandin analogues (Travatan® vs. Xalatan®) on ocular surface parameters. This study includes 44 eyes of 44 patients with newly diagnosed primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Patients were randomly divided into two groups and treated with either benzalkonium chloride (BAK)-preserved latanoprost and polyquad-preserved travoprost. Changes in intraocular pressure (IOP) levels and ocular surface parameters including ocular surface disease index (OSDI) questionnaire, tear breakup time (TBUT), ocular surface staining scores, and Schirmer test scores of patients were performed at baseline, 1, 3, 6, and 12months of treatment and compared. The age, sex ratio, visual acuity, central corneal thickness, and cup/disc ratio were similar between the groups. A decrease in IOP levels (23.3 ± 2.5 to 15.5 ± 2.3), TBUT (5.5 ± 2.3 to 4.1 ± 1.7s), Schirmer test values (11.3 ± 5.9 to 8.6 ± 4.7s), and a worsening in OSDI scores (44.6 ± 15.2 to 55.1 ± 13.1) and staining scores (1.7 ± 1.6 to 2.3 ± 1.8) were observed in all patients in the first month of treatment (p < 0.05, for all). No further worsening was detected during the 1-year follow-up. There was no difference between the groups in terms of alterations in IOP levels and ocular surface parameters. Travatan® and Xalatan® have a similar effect on IOP levels and ocular surface parameters in patients with POAG and OHT.

Highlights

Glaucoma is an optic neuropathy, which is the leading cause of irreversible blindness around the world
Changes in intraocular pressure (IOP) levels and ocular surface parameters including ocular surface disease index (OSDI) questionnaire, tear break-up time (TBUT), ocular surface staining scores, and Schirmer test scores of patients were performed at baseline, 1, 3, 6 and 12 months of treatment and compared
Travatan® and Xalatan® have a similar effect on IOP levels and ocular surface parameters in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT)

Summary

Introduction

Glaucoma is an optic neuropathy, which is the leading cause of irreversible blindness around the world. 60% of patients with glaucoma have ocular surface disease and its related symptoms including dryness, stinging, itching, burning, foreign body sensation, and visual disturbance [5,6,7] In the pathogenesis, both active ingredients and preservatives have toxic effects on the ocular surface; the direct relationship between the occurrence of iatrogenic dry eye and the number of drugs used in the therapy, regardless of the type of glaucoma medication, indicates that a common molecule found in eye drops, preservatives, is the main cause of the pathogenesis [3, 5, 8,9,10,11]. To compare the effect of two different prostaglandin analogues (Travatan® vs. Xalatan®) on ocular surface parameters

Objectives

Methods

Results

Conclusion